Close Menu

BEAMing

The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.

The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.

The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

As part of the CORRECT trial, researchers compared analyses of liquid and tissue biopsies, finding support for using circulating DNA to follow tumor progression.

Vall d'Hebron's Institute of Oncology will use the liquid biopsy-based OncoBEAM RAS test to research precision medicine approaches for metastatic colorectal cancer patients.

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

NEW YORK (GenomeWeb) — In a deal signed ceremoniously at the American Society of Clinical Oncology meeting earlier this week in Chicago, Merck and Sysmex Inostics will collaborate to develop and commercialize a kit to assay RAS mutations in circulating tumor DNA.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.